Skip to content

MDMA research published in 2023

Page 5 of 7: studies 81 to 100 of 125, newest first. Back to the MDMA overview

Studies

THE THERAPEUTIC POTENTIAL OF PSYCHEDELICS FOR MENTAL HEALTH DISORDERS: A REVIEW OF CURRENT EVIDENCE

PARIPEX INDIAN JOURNAL OF RESEARCH May 15, 2023 Chirag Ambaliya, Dimple Gupta, Ashok Vala et al.

The purpose of this review article is to give a summary of the literature on the use of psychedelic drugs, such as psilocybin, LSD, ayahuasca, and MDMA, in the treatment of various mental health conditions, such as depression, anxiety, PTSD, and substance use disorders. This review's main goal is to highlight recent human studies on the use of particular psychedelic drugs, like psilocybin, LSD,...

Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis

Cureus May 7, 2023 Suhwoo Bae, Michael Vaysblat, Ilja Dejanovic et al. 6 citations

Recreational drug use is a significant public health concern in various countries. It is well understood that usage of psychedelics/hallucinogens, such as lysergic acid diethylamide (LSD), ecstasy, phencyclidine (PCP), and psilocybin-containing mushrooms, has increased significantly over the last few decades, particularly in adolescents and young adults, yet the effects of these recreational...

(267) Ecstasy' - Accurate or Deceptive Name? A Systematic Review of MDMA Effects on the Male Sexual Response Cycle

The Journal of Sexual Medicine May 1, 2023 Julie Suyama, Alexandra Dubinskaya, Karyn Eilber et al.

3,4-Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’ or ‘Molly’) is a synthetic psychostimulant and entactogenic drug of abuse that augments feelings of pleasure, increases energy, and distorts sensory perception. MDMA increases serotonin, dopamine, and norepinephrine neurotransmission within the mesolimbic reward pathway, which impacts human sexual function. While dopamine is implicated as a...

Central Basis For MDMA (ecstasy) Induced Hyponatremia

Physiology May 1, 2023 Joshua Wyrosdic, Zahra Thirouin, Charles Bourque

Clinical studies have shown that hyponatremia can be induced by the ingestion of the recreational drug MDMA (3,4-Methyl​enedioxy​methamphetamine, ecstasy) when combined with a water intake (Baggot et al., 2016). However, the mechanisms by which MDMA induces hyponatremia is unknown. Hyponatremia is a life-threatening condition that causes rapid swelling of the brain and is commonly encountered...

Sentidos y vivencias relacionados con el uso recreativo de MDMA (Éxtasis)

Psicología Conocimiento y Sociedad May 1, 2023 Leticia Aszkinas Browarski, Juan Enrique Fernández 1 citation

Se presentan a continuación los resultados de un estudio exploratorio y descriptivo centrado en el análisis de los sentidos y vivencias asociados a experiencias de consumo de MDMA (3,4-metilendioximetanfetamina, Éxtasis) en usuarios jóvenes de esta sustancia que habitaban la ciudad de Montevideo en el período 2017-2019. Se desarrolló un muestreo no probabilístico en cadena que permitió la...

Withania somnifera influences MDMA-induced hyperthermic, cognitive, neurotoxic and neuroinflammatory effects in mice.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie May 1, 2023 Giulia Costa, Marcello Serra, Riccardo Maccioni et al. 13 citations

Withania somnifera (WS) is utilized in Ayurvedic medicine owing to its central and peripheral beneficial properties. Several studies have accrued indicating that the recreational amphetamine-related drug (+/-)- 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) targets the nigrostriatal dopaminergic system in mice, inducing neurodegeneration and gliosis, causing acute hyperthermia and cognitive...

LSD et MDMA en combinaison (Candy Flip)

Psychotropes April 21, 2023 Pierre Poloméni

Les adolescents et jeunes adultes participant à des événements musicaux consomment fréquemment des substances psychoactives pour améliorer la qualité des relations et des perceptions. Parmi ces substances, une association de LSD puis de MDMA, prises à une heure d’intervalle, dénommée Candy Flip, connue depuis longtemps, bénéficie d’une bonne réputation. Notre travail explore ces substances en...

Influence of adrenalectomy on the gut microbiome and MDMA-induced hyperthermia.

European Journal of Pharmacology April 15, 2023 Amal Aburahma, Srishti Rana, Ray A. Larsen et al. 5 citations

The increased use of the stimulant drug, 3,4-methylenedioxymethamphetamine (MDMA), more commonly known as Ecstasy, Molly or X, has been linked to the development of life-threatening hyperthermia in human and animal models. The current study aimed to investigate the role of the gut-adrenal axis in MDMA-induced hyperthermia by assessing the influence of the acute exogenous supplementation with...

Perspectives on the therapeutic potential of MDMA: A nation-wide exploratory survey among substance users

Frontiers in Psychiatry April 14, 2023 Jennifer L. Jones 4 citations

BackgroundAlcohol and other substance use disorders are commonly associated with post-traumatic stress disorder (PTSD), and the presence of these comorbidities is associated with worse treatment outcomes. Additionally, disparities in substance and PTSD prevalence have been associated with minority races and ethnicities, and minorities have been shown to be less likely to engage in treatment....

DOI: 10.3389/fpsyt.2023.1096298 (opens in new tab) Full text (opens in new tab) MDMA Race and ethnicity Viable treatment option Therapeutic potential +4

Orally Active Forms of DMT, 5-MeO-DMT, and Long-Acting MDMA for the Treatment of Neuropsychiatric Disorders.

ACS Medicinal Chemistry Letters April 13, 2023 Robert B. Kargbo 4 citations

This Patent Highlight describes derivatives of DMT, 5-MeO-DMT, and MDMA that are metabolically converted to biologically active analogs. When these prodrugs are administered to a subject, they potentially could be used therapeutically in conditions associated with neurological diseases. Furthermore, the disclosure provides methods to potentially treat conditions comprising major depressive...

DOI: 10.1021/acsmedchemlett.3c00077 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health treatment Drug development Therapeutic compounds

Dantrolene sodium fails to reverse robust brain hyperthermia induced by MDMA and methamphetamine in rats.

Psychopharmacology April 1, 2023 Keaton T Cameron-Burr, R Aaron Bola, Eugene A. Kiyatkin 5 citations

Hyperthermia induced by psychomotor stimulants may cause leakage of the blood-brain barrier, vasogenic edema, and lethality in extreme cases. Current treatments such as whole-body cooling are only symptomatic and a clear need to develop pharmacological interventions exists. Dantrolene sodium, a peripheral muscle relaxant used in the treatment of malignant hyperthermia, has been proposed as...

MDMA-assisted psychotherapy for post-traumatic stress disorder: The devil is in the detail.

Australian & New Zealand Journal of Psychiatry April 1, 2023 Gillinder Bedi, Susan M Cotton, Alexandre A. Guerin et al. 17 citations

Recent years have seen escalating media, public and scientific interest in psychedelic medicine. Australia and New Zealand have been late to this research; however, in the past 2 years, rapid developments suggest that this is changing. Here, we argue for the need to critically review existing evidence in this field to guide future directions. We focus on...

Role of 5-HT1A receptors in the basolateral amygdala on 3,4-methylenedioxymethamphetamine-induced prosocial effects in mice.

European Journal of Pharmacology March 10, 2023 Hirohito Esaki, Yuki Sasaki, Naoya Nishitani et al.

3,4-methylenedioxymethamphetamine (MDMA), a recreational drug, induces euphoric sensations and psychosocial effects, such as increased sociability and empathy. Serotonin, also called 5-hydroxytryptamine (5-HT), is a neurotransmitter that has been associated with MDMA-induced prosocial effects. However, the detailed neural mechanisms remain elusive. In the present study, we investigated whether...

DOI: 10.1016/j.ejphar.2023.175653 (opens in new tab) MDMA Animals Mice, inbred icr N-methyl-3,4-methylenedioxyamphetamine +8

MDMA, Internal Family Systems therapy, and the Minnesota model in the resolution of C-PTSD-induced alcohol and diazepam addiction—A retrospective case study

March 10, 2023 Mika Turkia 1 citation preprint

In February 2023, Australia became the first country in the world to allow psychiatrists to prescribe 3,4-methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD). This may have left interested clinicians looking for practical examples of the use of MDMA. In the 1950s and 1960s, psychedelics were successfully utilized in the treatment of alcoholism. This case study, the...

MDMA

Psychedelics as Psychiatric Medications March 1, 2023 Michael C Mithoefer, David E. Presti

Abstract MDMA (3,4-methylenedioxymethamphetamine) was originally synthesized and patented by the Merck chemical company in 1914. It was not explored for human use until the 1970–80s when there were published reports that it could be a useful catalyst to psychotherapy, in part because it often produced reduced anxiety and increased emotional openness. In 1985, in response to media attention to...

Evenings with Molly: Adult Couples' Use of MDMA for Relationship Enhancement.

Culture, Medicine, and Psychiatry March 1, 2023 Robert Colbert, Shannon Hughes 16 citations

Within the modern resurgence of psychedelics as medicinal agents for a range of conditions, the story of MDMA (Ecstasy, Molly) has been re-narrated from a dangerous street drug to a breakthrough mental health therapy. Even still, the story of MDMA remains incomplete within a binary discourse of deviant recreational use versus psychotherapeutic-medical use. The present research aimed to uncover...

DOI: 10.1007/s11013-021-09764-z (opens in new tab) Full text (opens in new tab) MDMA 3,4-methylene-dioxymethamphetamine Grounded theory Psychedelics

The Effects of Serotonergic Psychedelics on Neural Activity: A Meta-Analysis of Task-Based Functional Neuroimaging Studies

European Psychiatry March 1, 2023 J. H. Shepherd, Caitlin Baten, A. C. Klassen et al.

Introduction Curiosity toward the effects of psychedelic drugs on neural activation has increased due to their potential therapeutic benefits, particularly serotonergic psychedelics that act as 5-HT2A receptor agonists such as LSD, psilocybin, and MDMA. However, the pattern of their effects on neural activity in various brain regions in both clinical and healthy populations is still not well...

Psychedelics as Psychiatric Medications

March 1, 2023 David Nutt, David Castle 4 citations

Abstract There is substantial contemporary interest in psychedelic agents as medicines for maladies of the mind. This follows research in the 1950s and 1960s exploring the use of LSD and other psychedelics to treat a range of psychiatric illnesses as well as addictions. This research was shut down after prohibition of these drugs; however, the last decade has seen a major renewal of interest in...

Pharmacological effects of methylone and MDMA in humans

Frontiers in Pharmacology February 17, 2023 Lourdes Poyatos, Clara Pérez‐mañá, Olga Hladun et al. 26 citations

Methylone is one of the most common synthetic cathinones popularized as a substitute for 3,4-methylenedioxymethamphetamine (MDMA, midomafetamine) owing to its similar effects among users. Both psychostimulants exhibit similar chemistry (i.e., methylone is a β-keto analog of MDMA) and mechanisms of action. Currently, the pharmacology of methylone remains scarcely explored in humans. Herein, we...